Become a Member

Track your favourite stocks
Create & monitor portfolios
Daily portfolio value

Company	Chg	Chg %
Quickpicks
£	%
Add shares to your quickpicks to display them here!

Shield Thera (STX) Share News

IN BRIEF: Shield Therapeutics Chief Financial Officer Rudolf to leave

12th Oct 2023 11:14

Shield Therapeutics PLC - commercial-stage pharmaceutical company focusing on its iron deficiency product Accrufer - Chief Financial Officer Hans-Peter Rudolf will leave the company next week Friday to pursue other opportunities. The firm's company controller, Paul Spoors, will take on the CFO role on an interim basis. Shield says it has engaged an executive search firm to identify a new CFO. Read More

AIM WINNERS & LOSERS: Windward sees high contracting activity levels

12th Oct 2023 10:27

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday. Read More

TRADING UPDATES: Aston Martin CEO ups stake; Alkemy's lithium deal

3rd Oct 2023 17:14

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More

Shield Therapeutics completes USD20 million SWK financing

3rd Oct 2023 14:29

(Alliance News) - Shield Therapeutics PLC on Tuesday said it has now completed its USD20 million senior secured debt facility from SWK Funding LLC. Read More

UPDATE: Shield Therapeutics completes GBP5 million share placing

28th Sep 2023 14:54

(Alliance News) - Shield Therapeutics PLC on Thursday announced steps to improve its financial situation, as it revealed a slightly reduced loss in the first half of 2023. Read More

Shield Therapeutics raises funds for US sales push as loss narrows

28th Sep 2023 11:30

(Alliance News) - Shield Therapeutics PLC on Thursday announced steps to improve its financial situation, as it revealed a slightly reduced loss in the first half of 2023. Read More

UK earnings, trading statements calendar - next 7 days

21st Sep 2023 15:48

IN BRIEF: Shield Therapeutics changes reporting currency to US dollars

6th Sep 2023 20:33

Shield Therapeutics PLC - Gateshead Quays, England-based commercial stage pharmaceutical company focused on the commercialisation of its oral therapy for iron deficiency - Says it will change reporting currency to US dollars from pound sterling from 2023 results. Says the interim results for the first half of 2023 will include condensed and consolidated US dollar financial information for the period and full-year 2022. Read More

CORRECT: Biogens, Sage Therapeutics postpartum depression drug okayed

6th Aug 2023 17:07

(Correcting the name of Sage Therapeutics Inc. Please ignore incorrect coding of Shield Therapeutics PLC.) Read More

Biogens, Sage Therapeutics postpartum depression treatment approved

6th Aug 2023 14:17

(Alliance News) - The US Food & Drug Administration has approved Zurzuvae, zuranolone, 50 mg for adults with postpartum depression, Sage Therapeutics PLC and Biogen Inc said in a statement. Read More

IN BRIEF: Shield Therapeutics prescription orders up in first quarter

20th Jul 2023 11:43

Shield Therapeutics PLC - Gateshead Quays, England-based commercial stage pharmaceutical company focused on the commercialisation of its oral therapy for iron deficiency - Sees strong prescription growth in the second quarter and first half of 2023. Total prescriptions for second quarter increase 50% to 15,800 compared to the first quarter. In first half of 2023, total prescriptions grow to around 26,300 which exceeds total prescription volumes for all of 2022. The company says that this growth in the first half means Shield is likely to meet its 2023 goal for US Accrufer prescriptions. Read More

UK shareholder meetings calendar - next 7 days

21st Jun 2023 15:43

IN BRIEF: Shield Therapeutics pretax loss doubles despite revenue rise

27th Apr 2023 18:13

Shield Therapeutics PLC - Gateshead Quays, England-based commercial stage pharmaceutical company focused on the commercialisation of its oral therapy for iron deficiency - Reports revenue in the year to December 31 trebled to GBP4.5 million from GBP1.5 million a year before. Says net product revenue from sales of Accrufer in the US totalled GBP2.9 million, up from GBP0.1 million while royalty revenue from product sales in Europe reached GBP1.4 million, up from GBP0.9 million. Read More

IN BRIEF: Shield appoints Andy Hurley as chief commercial officer

5th Apr 2023 12:38

Shield Therapeutics PLC - Gateshead Quays, England-based commercial stage pharmaceutical company focused on the commercialisation of its oral therapy for iron deficiency - Appoints Andy Hurley as chief commercial officer, effective from April 10. Read More

FTSE 100 Latest

Value8,809.74

Change53.53